צמיחת הכנסות שנתית ב-12 החודשים האחרונים: NeuroSense Therapeutics (NRSN)

Adhering to biomedical ethical norms and ESG standards, NeuroSense Therapeutics (NRSN) is developing neuroprotection. The annual growth of operating sales revenue (TTM) on GURU.Markets reflects revenue dynamics, where 0.00 expresses the current value of the metric. High barriers to entry due to the cost of testing protect the business; however, the absence of current sales and linear growth in research expenses limit the company's operating leverage.
NeuroSense Therapeutics (NRSN) - פילוחי מדדים ודוחות פיננסיים

The development of drugs for neurodegenerative diseases is not subject to cyclicality or seasonality for NeuroSense Therapeutics (NRSN). This metric measures the percentage change in revenue over a rolling year, neutralizing short-term fluctuations. For the investor, this serves as an indicator of real business scaling, stripped of market noise. Research efficiency determines the company's fundamental growth. By analyzing the trajectory of year-over-year sales changes (TTM), one can assess the sustainability of the biotech's commercial progress.